| Bioactivity | MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) (IC50=0.41±0.05 μM). MY17 alleviates palmitic acid (PA) -induced insulin resistance by up-regulating the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT). By binding with PTP1B, MY17 can inhibit the activity of PTP1B, thereby improving insulin signaling and having anti-diabetic activity. MY17 can be used in the study of type 2 diabetes[1]. |
| Formula | C21H13N5O3S3 |
| Molar Mass | 479.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li M, et al. Identification of 1, 3, 4-Thiadiazolyl-Containing Thiazolidine-2, 4-dione Derivatives as Novel PTP1B Inhibitors with Antidiabetic Activity[J]. Journal of Medicinal Chemistry, 2024. |